Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Early Honebuto Draft Contains CEA Expansion, Ramp-Up of FIH Trial Sites
An early draft of this year’s Basic Policy on Economic and Fiscal Management and Reform (honebuto) includes wording calling for discussions on expanding the cost-effectiveness assessment (CEA) system and building new sites for first-in-human trials, it has been learned. The…
To read the full story
Related Article
- Japan OKs Honebuto Paper with Softened Phrasing on CEA, Sign of Change to Social Security Budgeting
June 16, 2025
- Latest Honebuto Draft Erases “Expansion” of CEA after LDP Pushback
June 12, 2025
- LDP Lawmakers Push Back on Honebuto Draft over CEA, Social Security Budgeting
June 10, 2025
- Honebuto Draft Urges Promotion of Drug Innovation, but Spells Out CEA Expansion Too
June 9, 2025
- Honebuto Outline Includes “Raise in Official Prices,” but Details Yet Unknown
May 27, 2025
REGULATORY
- MHLW Official Making Rounds to Rally Private Support for Drug Discovery Fund
January 21, 2026
- Cabinet OKs Subsidy to Boost Antibiotic API Stockpiles, Allocates 7.1 Billion Yen from Reserve
January 21, 2026
- PMDA Chief Vows Stronger Support for Drug Discovery, Orphan Designations
January 21, 2026
- AMED, JPMA Poised to Embed Pharma Expertise in Drug Discovery
January 20, 2026
- Japan’s Lower House Poll Set for Feb. 8 after Takaichi Calls Snap Vote
January 20, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…